These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 19383734

  • 1. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients.
    Raichlin E, Prasad A, Kremers WK, Edwards BS, Rihal CS, Lerman A, Kushwaha SS.
    Eur Heart J; 2009 Jun; 30(11):1356-63. PubMed ID: 19383734
    [Abstract] [Full Text] [Related]

  • 2. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 3. Discordant epicardial and microvascular endothelial responses in heart transplant recipients early after transplantation.
    Hollenberg SM, Tamburro P, Klein LW, Burns D, Easington C, Costanzo MR, Parrillo JE, Johnson MR.
    J Heart Lung Transplant; 1998 May 27; 17(5):487-94. PubMed ID: 9628567
    [Abstract] [Full Text] [Related]

  • 4. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec 27; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 5. Coronary endothelial vasomotor function and vascular remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression.
    Petrakopoulou P, Anthopoulou L, Muscholl M, Klauss V, von Scheidt W, Uberfuhr P, Meiser BM, Reichart B, Weis M.
    J Am Coll Cardiol; 2006 Apr 18; 47(8):1622-9. PubMed ID: 16631000
    [Abstract] [Full Text] [Related]

  • 6. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R.
    Clin Transplant; 2007 Apr 18; 21(4):536-43. PubMed ID: 17645716
    [Abstract] [Full Text] [Related]

  • 7. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 8. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 9. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 10. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction.
    Kim JW, Seo HS, Park JH, Na JO, Choi CU, Lim HE, Kim EJ, Rha SW, Park CG, Oh DJ.
    J Am Coll Cardiol; 2009 May 05; 53(18):1653-9. PubMed ID: 19406340
    [Abstract] [Full Text] [Related]

  • 11. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine.
    Ramzy D, Rao V, Tumiati LC, Xu N, Miriuka S, Delgado D, Ross HJ.
    Circulation; 2006 Jul 04; 114(1 Suppl):I214-9. PubMed ID: 16820575
    [Abstract] [Full Text] [Related]

  • 12. Vascular effects of cyclosporin A and acute rejection in canine heart transplantation.
    Bouchard D, Despatis MA, Buluran J, Cartier R.
    Ann Thorac Surg; 1997 Nov 04; 64(5):1325-30. PubMed ID: 9386698
    [Abstract] [Full Text] [Related]

  • 13. Coronary vasomotor response to phenylephrine in heart transplant patients.
    Aptecar E, Le Corvoisier P, Teiger E, Dupouy P, Vermes E, Sediame S, Hittinger L, Loisance D, Dubois-Rande JL, Montagne O.
    J Heart Lung Transplant; 2006 Aug 04; 25(8):912-20. PubMed ID: 16890111
    [Abstract] [Full Text] [Related]

  • 14. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J, Mohr FW, Gummert JF.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2011-7. PubMed ID: 17161355
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function.
    Petrakopoulou P, Kübrich M, Pehlivanli S, Meiser B, Reichart B, von Scheidt W, Weis M.
    Circulation; 2004 Sep 14; 110(11 Suppl 1):II207-12. PubMed ID: 15364864
    [Abstract] [Full Text] [Related]

  • 16. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.
    J Heart Lung Transplant; 2007 Oct 14; 26(10):998-1003. PubMed ID: 17919619
    [Abstract] [Full Text] [Related]

  • 17. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 14; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 18. Comparative effects of sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients.
    Joannides R, Etienne I, Iacob M, Hurault de Ligny B, Barbier S, Bellien J, Lebranchu Y, Thuillez C, Godin M.
    Transpl Int; 2010 Nov 14; 23(11):1135-43. PubMed ID: 20536790
    [Abstract] [Full Text] [Related]

  • 19. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S, Stephany B, Abu Romeh IS, Boumitri M, Yamani MH, Poggio ED.
    Clin Transplant; 2009 Nov 14; 23(3):351-60. PubMed ID: 19208105
    [Abstract] [Full Text] [Related]

  • 20. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial.
    Shenoy S, Hardinger KL, Crippin J, Desai N, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.
    Transplantation; 2007 May 27; 83(10):1389-92. PubMed ID: 17519792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.